Skip to main content
HR 2491 108th Congress House Health Administrative procedure Administrative remedies Antitrust law Civil actions and liability Commerce Consent decrees Department of Health and Human Services Drug approvals Drug industry Drugs Generic drugs Government Operations and Politics Intellectual property Law Marketing Patent infringement Patents Pharmaceutical research Punitive damages

Greater Access to Affordable Pharmaceuticals Act

Introduced: June 17, 2003 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 108th Congress ended
It never became law before the 108th Congress (2003–2004) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 25, 2003
Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Jun 24, 2003
Referred to the Subcommittee on Health.
Jun 17, 2003
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 17, 2003
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Greater Access to Affordable Pharmaceuticals Act - Amends the Federal Food, Drug, and Cosmetic Act to: (1) limit a brand name drug manufacturer to one Food and Drug Administration (FDA) 30-month stay of competition in a patent infringement suit against a generic drug applicant; (2) permit a generic applicant being sued to file a counterclaim to correct or delete patent information; (3) limit damages that a brand name manufacturer may recover in an instance where such manufacturer failed to file certain patent information; (4) permit a generic drug applicant to seek declaratory judgment regarding patent infringement prior to marketing a drug; (5) forfeit the180-day market exclusivity period for a first generic drug applicant to a subsequent generic applicant if the first applicant engages in certain activities which impede such drug's timely marketing; and (6) permit alternative means to determine bioequivalence for drugs that are not absorbed into the bloodstream.

What's happening now June 25, 2003

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

 Related & companion bills 1
  • S 1225 Identical bill Greater Access to Affordable Pharmaceuticals Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 7
All 7 Democratic 5 Republican 1 Independent 1
D
Schakowsky, Janice D.
Illinois · Oct 30, 2003
 D
DeLauro, Rosa L.
Connecticut · Jun 19, 2003
 D
Nadler, Jerrold
New York · Jun 19, 2003
 I
Sanders, Bernard
Vermont · Jun 19, 2003
 R
Calvert, Ken
California · Jun 17, 2003
 D
Markey, Edward J.
Massachusetts · Jun 17, 2003
 D
Pallone, Frank
New Jersey · Jun 17, 2003
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2491: Greater Access to Affordable Pharmaceuticals Act. 108th Congress. Open America. https://openamerica.io/bill/108-HR-2491/
MLA
"H.R. 2491: Greater Access to Affordable Pharmaceuticals Act." 108th Congress, 2026, Open America, https://openamerica.io/bill/108-HR-2491/.
Bluebook (legal)
H.R. 2491, 108th Cong. (2026), https://openamerica.io/bill/108-HR-2491/.
Markdown link
[H.R. 2491: Greater Access to Affordable Pharmaceuticals Act](https://openamerica.io/bill/108-HR-2491/)
Report a problem